All In Biotech

Drug Trial Radar · NCT06676319

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

A Randomized, Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Investigate the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig (SAR443765) in Adult Participants With High-risk Asthma Who Are Not Currently Eligible for Biologic Treatment

Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 556 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

556

Actual

Start

Nov 7, 2024

Primary completion

Jun 21, 2027

Study completion Jul 19, 2027

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Nov 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a parallel-group, Phase 2, randomized, double-blind, placebo-controlled, 2-arm study for the treatment of asthma. The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with subcutaneous (SC) lunsekimig compared with placebo in male and female participants (aged 18 to 80 years, inclusive) with asthma, who are not currently eligible for biologic treatments. Study details include: * The study duration will be approximately 64 weeks for participants not transitioning into the LTS study and approximately 60 weeks for participants transitioning into the LTS study. * The investigational treatment duration will be up to approximately 52 weeks. * The number of visits will be 18.

Conditions

  • Asthma

Interventions

  • LunsekimigDrug

    Pharmaceutical form: Solution for injection in vial; Route of administration: Subcutaneous injection

  • Short-Acting Beta Agonists (SABA)Drug

    Pharmaceutical form: Varies and depends on pharmaceutical presentation; Route of administration: Oral Inhalation

  • PlaceboDrug

    Pharmaceutical form: Solution for injection in vial; Route of administration: Subcutaneous injection

  • Fluticasone/SalmeterolDrug

    Pharmaceutical form: Varies and depends on pharmaceutical presentation; Route of administration:Oral Inhalation

  • Budesonide/FormoterolDrug

    Pharmaceutical form: Varies and depends on pharmaceutical presentation; Route of administration: Oral Inhalation

  • Budesonide/AlbuterolDrug

    Pharmaceutical form: Aerosol for inhalation; Route of administration: Oral Inhalation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized rate of asthma exacerbation eventsTime frame: From baseline up to 52 weeks

Locations

221 sites in 22 countries. Site status is shown where the registry gives one.

  • The Center for Clinical Trials - Saraland- Site Number : 8400096

    Saraland, Alabama

  • Chandler Clinical Research Trials- Site Number : 8400075

    Chandler, Arizona

  • Epic Medical Research - Sun City- Site Number : 8400052

    Sun City, Arizona

  • Tucson Clinical Research Institute- Site Number : 8400085

    Tucson, Arizona

  • Ark Clinical Research- Site Number : 8400097

    Long Beach, California

  • Downtown L.A. Research Center- Site Number : 8400080

    Los Angeles, California

  • Carbon Health - North Hollywood - NoHo West- Site Number : 8400061

    North Hollywood, California

  • Carbon Health - San Mateo - Hillsdale Mall- Site Number : 8400062

    San Mateo, California

  • Stanford University Medical Center- Site Number : 8400108

    Stanford, California

  • Modena Allergy And Asthma- Site Number : 8400068

    Torrance, California

  • Howard University Hospital- Site Number : 8400107

    Washington D.C., District of Columbia

  • Helix Biomedics- Site Number : 8400005

    Boynton Beach, Florida

  • Beautiful Minds Clinical Research Center- Site Number : 8400019

    Cutler Bay, Florida

  • Omega Research Consultants - Debary - North Charles Richard Beall Boulevard- Site Number : 8400082

    DeBary, Florida

  • Alfa Medical Research- Site Number : 8400071

    Hollywood, Florida

  • Royal Clinical Trials - Inverness- Site Number : 8400067

    Inverness, Florida

  • Premier Medical Associates- Site Number : 8400077

    Lady Lake, Florida

  • D&H Pompano Research Center- Site Number : 8400072

    Margate, Florida

  • Research Institute of South Florida- Site Number : 8400023

    Miami, Florida

  • Innovations Biotech- Site Number : 8400044

    Miami, Florida

  • Tellabio International Research Services- Site Number : 8400083

    Pembroke Pines, Florida

  • Avanza Medical Research Center- Site Number : 8400056

    Pensacola, Florida

  • Ilumina Medical Research- Site Number : 8400095

    Saint Cloud, Florida

  • Private Practice - Dr. David Kavtaradze- Site Number : 8400081

    Cordele, Georgia

  • EmVenio Research - Riverdale- Site Number : 8400109

    Riverdale, Georgia

  • Christie Clinic in Champaign on University- Site Number : 8400003

    Champaign, Illinois

  • University of Kansas Medical Center- Site Number : 8400105

    Kansas City, Kansas

  • Velocity Clinical Research - Rockville (formerly Meridian Clinical Research)- Site Number : 8400036

    Rockville, Maryland

  • Javara - Privia Medical Group - Silver Spring Lockwood- Site Number : 8400042

    Silver Spring, Maryland

  • University of Michigan Health System - Ann Arbor- Site Number : 8400014

    Ann Arbor, Michigan

  • Clarkston Medical Group- Site Number : 8400054

    Clarkston, Michigan

  • Javara - Mankato Clinic- Site Number : 8400001

    Mankato, Minnesota

  • Mayo Clinic in Rochester - Minnesota- Site Number : 8400057

    Rochester, Minnesota

  • Hannibal Regional Healthcare System- Site Number : 8400078

    Hannibal, Missouri

  • Icahn School of Medicine at Mount Sinai (ISMMS) - Mount Sinai Doctors- Site Number : 8400069

    New York, New York

  • Pioneer Clinical Research - New York- Site Number : 8400092

    New York, New York

  • Piedmont Healthcare - Family Medicine- Site Number : 8400064

    Statesville, North Carolina

  • Cleveland Clinic - Cleveland- Site Number : 8400106

    Cleveland, Ohio

  • Asthma & Allergy Center - Toledo- Site Number : 8400020

    Toledo, Ohio

  • OK Clinical Research- Site Number : 8400060

    Edmond, Oklahoma

Showing 40 of 221 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.